Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease

Toxicology Letters

Volumn 139, Issue 2-3, 2003, Pages 135-151

  Eberhardt, Olaf ^a   Schulz, Jörg B ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Animal models; Apoptosis; Cell death; MPTP; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; NITRIC OXIDE; PROTEIN BAX; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 4; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; CELL CULTURE; CELL DEATH; CONFERENCE PAPER; DEGENERATIVE DISEASE; DNA STRAND BREAKAGE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; APOPTOSIS; CASPASES; CELL CYCLE; INFLAMMATION; NITRIC OXIDE; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0037418614     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(02)00428-9     Document Type: Conference Paper

References (135)

1. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
2. Alexi T., Borlongan C.V., Faull R.L.M., Williams C.E., Clark R.G., Gluckman P.D., Hughes P.E. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Progr. Neurobiol. 60:2000;409-470.
3. Andersen J.K. Does neuronal loss in Parkinson's disease involve programmed cell death? BioEssays. 23:2001;640-646.
4. Andringa, G., Cools, A.R., 2000. The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey, J. Neural Transm. 60 Suppl. 215-225.
5. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12:1997;25-31.
6. Baloh R.H., Enomoto H., Johnson E.M. Jr, Milbrandt J. The GDNF family ligands and receptors - implications for neural development. Curr. Opin. Neurobiol. 10:2000;103-110.
7. Banati R.B., Daniel S.E., Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13:1998;221-227.
8. Banati R.B., Blunt S., Graeber M.B. What does apoptosis have to do with Parkinson's disease? Mov. Disord. 14:1999;384-385.
9. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
10. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.-J., Mallet J., Horellou P. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 94:1997;8818-8823.
11. Bilsland J., Roy S., Xanthoudakis S., Nicholson D.W., Han Y., Grimm E., Hefti F., Harper S. Caspase inhibitors attenuate 1-methyl-4-phenyl-pyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. J. Neurosci. 22:2002;2637-2649.
12. Björklund A., Kirik D., Georgievska B., Lundberg C., Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886:2000;82-98.
13. Blum D., Torch S., Lambeng N., Nissou M.-F., Benabid A.-L., Sadoul R., Verna J.-M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progr. Neurobiol. 65:2001;135-172.
14. Burke R.E. Programmed cell death and Parkinson's disease. Mov. Disord. 13:(Suppl. 1):1998;17-23.
15. Burke R.E., Macaya A., DeVivo D., Kenyon N., Janec E.M. Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons. Neuroscience. 50:1992;559-569.
16. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Nature. 80:1983;4546-4550.
17. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta. 1453:1999;49-62.
18. +-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res. 57:1999;86-94.
19. Choi-Lundberg D.L., Lin Q., Chang Y.-N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., Bohn M.C. Dopaminergic neurons are protected from degeneration by GDNF gene therapy. Science. 275:1997;838-841.
20. von Coelln R., Kügler S., Bähr M., Weller M., Dichgans J., Schulz J.B. Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. J. Neurochem. 77:2001;263-273.
21. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74:2000;2213-2216.
22. Deveraux Q.L., Reed J.C. IAP family proteins - suppressors of apoptosis. Genes Dev. 13:1999;239-252.
23. Deveraux Q.L., Roy N., Stennicke H.R., van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17:1998;2215-2223.
24. Dickens M., Rogers J.S., Cavanagh J., Raitano A., Xia Z., Halpern J.R., Greenberg M.E., Sawyers C.L., Davis R.J. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science. 277:1997;693-696.
25. Dodel R.C., Du Y., Bales K.R., Ling Z.D., Carvey P.M., Paul S.M. Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinium-induced toxicity of cultured fetal rat mesencephalic dopamine neurons. Neuroscience. 86:1998;701-707.
26. Du Y., Dodel R.C., Bales K.R., Jemmerson R., Hamilton-Byrd E., Paul S.M. Involvement of a caspase-3-like cysteine protease in 1-methyl-4-pyridinium-mediated apoptosis of cultured cerebellar granule neurons. J. Neurochem. 69:1997;1382-1388.
27. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L.G., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocyclin prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;14669-14674.
28. Duan W., Zhang Z., Gash D.M., Mattson M.P. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann. Neurol. 46:1999;587-597.
29. Dunnett S.B., Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature (Suppl.). 399:1999;A32-A39.
30. Eberhardt O., von Coelln R., Kügler S., Lindenau J., Rathke-Hartlieb S., Gerhardt E., Haid S., Isenmann S., Gravel C., Srinivasan A., Weller M., Bähr M., Dichgans J., Schulz J.B. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 20:2000;9126-9134.
31. Estus S., Zaks W.J., Freeman R.S., Gruda M., Bravo R., Johnson E.M. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J. Cell Biol. 127:1994;1717-1727.
32. +-induced apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res. 55:1999;620-628.
33. Forno L.S., Langston J.W., DeLanney L.E., Irwin I. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res. 448:1988;150-157.
34. +-induced apoptosis. NeuroReport. 12:2001;2049-2052.
35. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 380:1996;252-255.
36. Gerhardt G.A., Cass W.A., Huettl P., Brock S., Zhang Z., Gash D.M. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res. 817:1999;163-171.
37. Gerhardt E., Kügler S., Leist M., Beier C., Berliocchi L., Volbracht C., Weller M., Bähr M., Nicotera P., Schulz J.B. Cascade of caspase-activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis. Mol. Cell Neurosci. 17:2001;717-731.
38. Gomez C., Reiriz J., Gil J., Ferrer I., Ambrosio S. Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. 63:2001;421-428.
39. Greenamyre J.T. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology. Funct. Neurol. 15:2000;67-80.
40. Grünblatt, E., Mandel, S., Berkuzki, T., Youdim, M.B., 1999. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14, 612-618.
41. Guo Q., Fu W., Xie J., Luo H., Sells S.F., Geddes J.W., Bondada V., Rangnekar V.M., Mattson M.P. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat. Med. 4:1998;957-962.
42. Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R.T., Beal M.F. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2:1996;1017-1021.
43. Hartley, A., Stone, J.m, Heron, C., Cooper, J.M., Schapira, A.H., 1994. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J. Neurochem. 63, 1987-1990.
44. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., Hirsch E.C. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. USA. 97:2000;2875-2880.
45. Hartmann A., Michel P.P., Troadec J.D., Mouatt-Prigent A., Faucheux B.A., Ruberg M., Agid Y., Hirsch E.C. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J. Neurochem. 76:2001;1785-1793.
46. Hartmann A., Troadec J.D., Hunot S., Kikly K., Faucheux B.A., Mouatt-Prigent A., Ruberg M., Agid Y., Hirsch E.C. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J. Neurosci. 21:2001;2247-2255.
47. Hassouna I., Wickert H., Zimmermann M., Gillardon F. Increase in Bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci. Lett. 204:1996;85-88.
48. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
49. Hengartner M.O. The biochemistry of apoptosis. Nature. 407:2000;770-776.
50. Herdegen T., Claret F.-X., Kallunki T., Martin-Villalba A., Winter C., Hunter T., Karin M. Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. J. Neurosci. 18:1998;5124-5135.
51. Hirsch E.C., Hunot S., Faucheux B., Agid Y., Mizuno Y., Mochizuki H., Tatton W.C., Tatton N., Olanow W.C. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord. 14:1999;383-384.
52. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.-P., Ruberg M., Faucheux B.A., Agid Y., Hirsch E.C. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA. 94:1997;7531-7536.
53. Inoue T., Tsui J., Wong N., Wong S.Y., Suzuki F., Kwok Y.N. Expression of glial cell-line derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment. Brain Res. 826:1999;306-308.
54. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:1995;257-269.
55. Jellinger K.A. Cell death mechanisms in Parkinson's disease. J. Neural Transm. 107:2000;1-29.
56. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13:(Suppl. 1):1998;24-34.
57. Kahns S., Lykkebo S., Jakobsen L.D., Nielsen M.S., Jensen P.H. Caspase-mediated parkin cleavage in apoptotic cell death. J. Biol. Chem. 277:2002;15303-15308.
58. Kaufmann S.H., Hengartner M.O. Programmed cell death: alive and well in the new millenium. Trends Cell Biol. 11:2001;526-534.
59. Kingsbury A.E., Marsden C.D., Foster O.J.F. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov. Disord. 13:1998;877-884.
60. Klevenyi P., Andreassen O., Ferrante R.J., Schleicher J.R. Jr, Friedlander R.M., Beal M.F. Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. NeuroReport. 10:1999;635-638.
61. Klivenyi P., Beal M.F., Ferrante R.J., Andreassen O.A., Wermer M., Chin M.-R., Bonventre J.V. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. J. Neurochem. 71:1998;2634-2637.
62. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology. 39:1998;167-180.
63. Kojima H., Abiru Y., Sakajiri K., Watabe K., Ohishi N., Takamori M., Hatanaka H., Yagi K. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem. Biophys. Res. Commun. 238:1997;569-573.
64. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., Gudkov A.V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 285:1999;1733-1737.
65. Kordower J.H., Emborg M.E., Bolch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
66. Kosel S., Egensperger R., Voneitzen U., Mehraein P., Graeber M.B. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol. 93:1997;105-108.
67. Kügler S., Meyn L., Holzmüller H., Gerhardt E., Isenmann S., Schulz J.B., Bahr M. Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors. Mol. Cell Neurosci. 17:2001;78-96.
68. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46:1999;598-605.
69. Leist M., Single B., Castoldi A.F., Kuhnle S., Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 185:1997;1481-1486.
70. Leist M., Volbracht C., Fava E., Nicotera P. 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis. Mol. Pharmacol. 54:1998;789-801.
71. Le-Niculescu H., Bonfoco E., Kasuya Y., Claret F.-X., Green D.R., Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell Biol. 19:1999;751-763.
72. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat. Med. 5:1999;1403-1409.
73. Lin L.-F.H., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
74. Luo Y., Umegaki H., Wang X., Abe R., Roth G.S. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 273:1998;3756-3764.
75. Mandel S., Grünblatt E., Youdim M. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J. Neural Transm. (Suppl.). 60:2000;117-124.
76. Mandir A.S., Przedborski S., Jackson-Lewis V., Wang Z.-Q., Simbulan-Rosenthal C.M., Smulson M.E., Hoffman B.E., Guastella D.B., Dawson V.L. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl. Acad. Sci. USA. 96:1999;5774-5779.
77. Marshall K.A., Daniel S.E., Cairns N., Jenner P., Halliwell B. Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease. Biochem. Biophys. Res. Commun. 240:1997;84-87.
78. Mattson M. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1:2000;120-129.
79. Miao N., Wang M., Ott J.A., D'Alessandro J.S., Woolf T.M., Bumcrot D.A., Mahanthappa N.K., Pang K. Sonic hedgehog promotes the survival of specific CNS neuron populations and protects these cells from toxic insult in vitro. J. Neurosci. 17:1997;5891-5899.
80. Mielke K., Herdegen T. JNK and p38 stress kinases-degenerative effectors of signal-transduction-cascades in the nervous system. Progr. Neurobiol. 61:2000;45-60.
81. Miller F.D., Pozniak C.D., Walsh G.S. Neuronal life and death: an essential role for the p53 family. Cell Death Differ. 7:2000;880-888.
82. Mochizuki H., Mori H., Mizuno Y. Apoptosis in neurodegenerative disorders. J. Neural Transm. (Suppl.). 50:1997;125-140.
83. Mochizuki H., Hayakawa H., Migita M., Shibata M., Tanaka R., Suzuki A., Shimo-Nakanishi Y., Urabe T., Yamada M., Tamayose K., Shimada T., Miura M., Mizuno Y. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;10918-10923.
84. Morrison R.S., Kinoshita Y. The role of p53 in neuronal cell death. Cell Death Differ. 7:2000;868-879.
85. Mukherjee S.K., Klaidman L.K., Yasharel R., Adams J.D. Jr. Increased brain NAD prevents neuronal apoptosis in vivo. Eur. J. Pharmacol. 330:1997;27-34.
86. Nicholson D.W. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6:1999;1028-1042.
87. Obinu M.C., Reibaud M., Blanchard V., Moussaoui S., Imperato A. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Mov. Disord. 17:2002;13-19.
88. Offen D., Beart P.M., Cheung N.S., Pascoe C.J., Hochman A., Gorodin S., Melamed E., Bernard R., Bernard O. Trangenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc. Natl. Acad. Sci. USA. 95:1998;5789-5794.
89. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.-S. Mouse model of parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience. 106:2001;589-601.
90. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov. Disord. 13:(Suppl. 1):1998;35-38.
91. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1992;1658-1667.
92. Przedborski S., Jackson-Lewis V., Yokohama R., Shibata T., Dawson V.L. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA. 93:1996;4565-4571.
93. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., Souza J.M., Jackson-Lewis V.V., Lee V.M., Ischiropoulos H. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76:2001;637-640.
94. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a review of its utility and safety. J. Neurochem. 76:2001;1265-1274.
95. Ryan K.M., Phillips A.C., Vousden K.H. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13:2001;332-337.
96. Robertson G.S., Crocker S.J., Nicholson D.W., Schulz J.B. Neuroprotection by the inhibition of apoptosis. Brain Pathol. 10:2000;283-292.
97. Sadoul R. BCL-2 family members in the development and degenerative pathologies of the nervous system. Cell Death Differ. 5:1998;805-815.
98. Salinas M., Martin D., Alvarez A., Cuadrado A. Akt/PKBalpha protects PC12 cells against the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium and reduces the levels of oxygen-free radicals. Mol. Cell Neurosci. 17:2001;67-77.
99. Saporito M.S., Brown E.M., Miller M.S., Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyltetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288:1999;421-427.
100. Saporito M.S., Thomas B.A., Scott R.W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 75:2000;1200-1208.
101. Sanna M.G., Duckett C.S., Richter B.W.M., Thompson C.B., Ulevitch R.J. Selective activation of JNK1 is necessary for the anti-apoptotic activity of hILP. Proc. Natl. Acad. Sci. USA. 95:1998;6015-6020.
102. Schulz J.B., Gerhardt E. Apoptosis: its relevance to Parkinson's disease. Clin. Neurosci. Res. 1:2001;427-433.
103. Schulz J.B., Henshaw D.R., Matthews R.T., Beal M.F. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. 132:1995;279-283.
104. Schulz J.B., Matthews R.T., Muqit M.M., Browne S.E., Beal M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64:1995;936-939.
105. Seaton T.A., Cooper J.M., Schapira A.H.V. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777:1997;110-118.
106. Seimiya H., Mashima T., Toho M., Tsuruo T. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J. Biol. Chem. 272:1997;4631-4636.
107. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 527:1990;7-20.
108. + induced apoptotic cell death in SH-SY5Y neuroblastoma cells: an electron microscope study. J. Neurosci. Res. 48:1997;226-237.
109. Simons M., Beinroth S., Gleichmann M., Liston P., Korneluk R.G., MacKenzie A.E., Bähr M., Klockgether T., Robertson G.S., Weller M., Schulz J.B. Adenovirus-mediated gene transfer of IAPs delays apoptosis of cerebellar granule neurons. J. Neurochem. 72:1999;292-301.
110. + inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). Exp. Cell Res. 250:1999;75-85.
111. +) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol. Aging. 14:1993;295-301.
112. Tatton N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166:2000;29-43.
113. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 77:1997;1037-1048.
114. Thornberry N.A. Caspases: key mediators of apoptosis. Chem. Biol. 5:1998;R97-R103.
115. Thornberry N.A., Rano T.A., Peterson E.P., Rasper D.M., Timkey T., Garcia-Calvo M., Houtzager V.M., Nordstrom P.A., Roy S., Vaillancourt J.P., Chapman K.T., Nicholson D.W. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272:1997;17907-17911.
116. Teismann P., Schwaninger M., Weih F., Ferger B. Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. Neuroreport. 12:2001;1049-1053.
117. Tomac A., Lindquist E., Lin L.-F.H., Ögren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 373:1995;335-339.
118. Tompkins M., Basgall E., Zamrini E., Hill W. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am. J. Pathol. 150:1997;119-131.
119. Trimmer P.A., Smith T.S., Bennett J.P. Jr. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration. 5:1996;233-239.
120. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418.
121. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74:(2):2000;721-729.
122. Vila M., Jackson-Lewis V.V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;2837-2842.
123. Virdee K., Bannister A.J., Hunt S.P., Tolkovsky A.M. Comparison between the timing of JNK activation, c-jun phosphorylation, and onset of death commitment in sympathetic neurones. J. Neurochem. 69:1997;550-561.
124. Visvanath V., Wu Y., Boonplueang R., Chen S., Stevenson F.F., Yantiri F., Yang L., Beal M.F., Andersen J.K. Caspase-9 activation results in downstream caspase activation and Bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci. 21:2001;9519-9528.
125. Waldmeier P.C., Spooren W.P., Hengerer B. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. Naunyn Schmiedebergs Arch. Pharmacol. 362:2000;526-537.
126. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22:2002;1763-1771.
127. + toxicity in nigral dopaminergic neurones. NeuroReport. 7:1996;921-923.
128. Wüllner U., Kornhuber J., Weller M., Schulz J.B., Löschmann P.-A., Riederer P., Klockgether T. Cell death and apoptosis regulating proteins in Parkinson's disease - a cautionary note. Acta Neuropathol. 97:1999;408-412.
129. Xia X.G., Harding T., Weller M., Uney J.B., Schulz J.B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;10433-10438.
130. Yang D.D., Kuan C.Y., Whitmarsh A.J., Rincon M., Zheng T.S., Davis R.J., Rakic P., Flavell R.A. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature. 389:1997;865-870.
131. Yang L., Matthews R.T., Schulz J.B., Klockgether T., Liao A.W., Martinou J.-C., Penney J.B. Jr, Hyman B.T., Beal M.F. MPTP neurotoxicity is attenuated in mice overexpressing Bcl-2. J. Neurosci. 18:1998;8145-8152.
132. Yap D.B.S., Hsieh J.-K., Chan F.S.G., Lu X. Mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene. 18:1999;7681-7689.
133. Yu Z., Zhou D., Bruce-Keller A.J., Kindy M.S., Mattson M.P. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J. Neurosci. 19:1999;8856-8865.
134. Zhang Y., Zhou L., Miller C.A. A splicing variant of a death domain protein that is regulated by a mitogen-activated kinase is a substrate for c-Jun N-terminal kinase in the human central nervous system. Proc. Natl. Acad. Sci. USA. 95:1998;2586-2591.
135. Zigmond M.J., Stricker E.M. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int. Rev. Neurobiol. 31:1989;1-79.